Group 1 - The company reported revenue of approximately 9.843 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 11.7% [1] - Profit attributable to owners increased to 78.117 million RMB, a significant year-on-year growth of 258% [1] - Adjusted net profit under non-IFRS was approximately 122 million RMB, reflecting a year-on-year increase of 33.2% [1] Group 2 - The company's gross profit rose by 25.3% to 1.1045 billion RMB, with the gross margin increasing from 10.0% to 11.2% [1] - The growth in gross margin is primarily attributed to strong downstream demand for the company's proprietary brand products, which has led to an expansion in the scale of high-margin business [1]

Core Viewpoint - The company reported a revenue of RMB 9.843 billion, representing a year-on-year growth of 11.7%, and a net profit attributable to shareholders of RMB 78.117 million, which is a significant increase of 258% [1] Group 1: Industry Overview - The Chinese pharmaceutical and healthcare industry faces both opportunities and challenges in the first half of 2025, driven by ongoing efforts to enhance grassroots medical systems and social security [1] - The "Healthy China 2030" strategy and policies promoting accessible healthcare are leading to structural changes in the pharmaceutical industry, aligning with the company's long-term strategy to improve drug accessibility [1] - Economic downturns and adjustments in medical insurance policies are causing a temporary slowdown in growth within the pharmaceutical and healthcare sectors, emphasizing the need for quality improvement and efficiency [1] Group 2: Company Strategy and Performance - The company has navigated a challenging market environment by leveraging its leading omnichannel strategy and focusing on core business areas [2] - Innovations and service upgrades across the pharmaceutical supply chain have been implemented, enhancing collaboration with upstream and downstream partners to reach a broader and more diverse user base [2] - The company is committed to upgrading user experience and reducing costs within the industry, driving value creation and collaboration through a strategy centered on "technology-driven + ecological collaboration" [2]

格隆汇8月20日丨药师帮(09885.HK)发布公告，截至2025年6月30日止六个月，实现收入人民币98.43亿 元，同比增加11.7%；毛利为人民币11.05亿元，同比增加25.3%；公司拥有人应占利润人民币7811.7万 元，同比增加258.0%；经调整净利润人民币1.22亿元，同比增加33.2%；每股盈利人民币0.11元。 报告期内，集团录得收入增加主要归因于：(i)报告期内自营业务持续稳定发展；及(ii)集团的收购事项 为集团收入增长注入新动力。集团自营业务的收入由截至2024年6月30日止六个月的人民币83.45亿元增 加12.5%至截至2025年6月30日止六个月的人民币93.89亿元，主要归因于：(i)买家群体扩大以及物流及 客户服务等买家体验持续优化；(ii)自营业务的月付费买家数量比去年同期持续稳定增加；及(iii)集团的 收购事项为集团收入增长注入新动力。 ...

Core Insights - The company reported a revenue of RMB 9.843 billion, representing a year-on-year growth of 11.7% [1] - Shareholder profit reached RMB 78.117 million, with a significant year-on-year increase of 258% [1] - Earnings per share stood at RMB 0.11 [1] Industry Overview - The Chinese pharmaceutical and healthcare industry faces both opportunities and challenges in the first half of 2025, driven by ongoing efforts to enhance grassroots medical systems and social security [1] - The "Healthy China 2030" strategy and policies promoting accessible healthcare are leading to structural changes in the pharmaceutical sector, aligning with the company's long-term strategy to improve drug accessibility [1] - Economic downturns and adjustments in medical insurance policies are causing a temporary slowdown in growth within the pharmaceutical and healthcare industry, emphasizing the need for quality improvement and efficiency [1] Company Strategy - The company has navigated a challenging market environment by leveraging its leading omnichannel strategy and focusing on core business areas [2] - Innovations and service upgrades across the pharmaceutical supply chain have been prioritized, enhancing collaboration with upstream and downstream partners [2] - The company aims to provide comprehensive digital solutions to a broader and more diverse user base, emphasizing user experience and cost reduction [2] - A core strategy of "technology-driven + ecological collaboration" has led to breakthroughs in scale expansion, profit optimization, and technology implementation [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何 責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 截 至2025年6月30日止六個月 中期業績公告 藥師幫股份有限公司（「本公司」，連 同 其 附 屬 公 司 及 綜 合 聯 屬 實 體 統 稱「本 集 團」）董 事（「董 事」）會（「董事會」）欣然宣佈本集團截至2025年6月30日止六個月（「報 告 期」）的 未 經 審 計 中 期 業 績。該 等 中 期 業 績 已 由 本 公 司 審 計 委 員 會（「審計委員 會」）及本公司審計師德勤 • 關黃陳方會計師行（「審計師」）審 閱。 除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 本 公 司 日 期 為2023年6月15日的招股章程 （「招股章程」）所 界 定 者 具 相 同 涵 義。 摘 要 | 至6月3 ...

Core Viewpoint - The stock of Yaoshi Bang (09885) has risen nearly 6%, currently trading at HKD 9.74, following the announcement of its inclusion in the MSCI China Small Cap Index, effective after the market close on August 26 [1] Group 1: Company Performance - Yaoshi Bang expects a significant increase in profit, projecting at least RMB 70 million for the half-year ending June 30, 2025, which is more than three times the RMB 21.8 million profit for the half-year ending June 30, 2024 [1] - The company has reported strong growth in its self-owned brand business, with GMV reaching RMB 717 million from January to April 2025, representing a year-on-year increase of 108.1% [1] - The self-owned brand business GMV has shown exceptional growth, reaching RMB 560 million, with a year-on-year increase of 532.3% [1] Group 2: Market Position - Longcheng Securities highlights Yaoshi Bang as a leader in the digital ecosystem construction of the domestic off-hospital pharmaceutical industry, indicating robust growth in both platform and self-operated businesses [1] - The company is transitioning from a strategy focused on "scale expansion" to one aimed at "profit enhancement," reflecting a strategic upgrade in its business model [1]

Group 1 - The core viewpoint of the article highlights that Yaoshi Bang (09885) has seen a nearly 6% increase in stock price, attributed to its inclusion in the MSCI China Small Cap Index and a positive earnings forecast [1][1][1] - The company expects its profit attributable to shareholders for the half-year ending June 30, 2025, to be no less than RMB 70 million, which is more than three times the RMB 21.8 million profit expected for the half-year ending June 30, 2024 [1][1][1] - Longcheng Securities identifies Yaoshi Bang as a leader in the digital ecosystem construction of the domestic off-hospital pharmaceutical industry, noting steady growth in both its platform and self-operated businesses [1][1][1] Group 2 - The company is undergoing a strategic upgrade from "scale expansion" to "profit enhancement," with its proprietary brand business showing high growth [1][1][1] - For the period from January to April 2025, the company's GMV for its proprietary brand business reached RMB 717 million, representing a year-on-year growth of 108.1% [1][1][1] - The GMV for the company's proprietary brand business alone reached RMB 560 million, with a remarkable year-on-year growth of 532.3% [1][1][1]

据悉，MSCI中国小盘股指数成分股筛选严格，调整频繁，紧跟市场动态，是众多国际投资机构的投资 参考依据。指数基金和被动型基金通常会根据指数成分股进行投资，因此纳入指数有望带来更多的被动 资金流入。5月份调整中获纳入的生物制药企业复宏汉霖，自生效日后的累计涨幅超60%。 药师帮获纳入MSCI中国小盘股指数，是资本市场对公司经营业绩及发展潜力的认可，将有助于公司拓 宽投资者基础，进一步增进个股流动性，提升资本市场影响力。药师帮近期发布的公告显示，公司今年 上半年净利润预期将不少于人民币7000万元，为上年同期3.2倍以上。在医药流通市场普遍承压的背景 下，药师帮凭借"平台+自营+自有品牌"驱动模式以及独特的现金周转能力逆势增长。 近日，MSCI系列指数公布了8月份指数审议结果。在本次调整中，MSCI中国指数新纳入地平线机器 人、老铺黄金、三生制药等14只股票；药师帮、迈富时等19只港股获纳入MSCI中国小盘股指数，相关 调整将于8月26日收盘后正式生效。 MSCI中国小盘股指数是由摩根士丹利资本国际公司（MSCI）编制的跟踪中国小盘股票表现的国际化指 数，隶属于MSCI全球小型股指数（MSCI Global Sm ...

Core Viewpoint - The company, Yaoshi Bang (09885.HK), has announced a board meeting scheduled for August 20, 2025, to consider and approve its interim results for the six months ending June 30, 2025, and to discuss the potential declaration of an interim dividend, if any [1] Group 1 - The board meeting will focus on the approval of the group's interim performance for the first half of 2025 [1] - The meeting will also consider the declaration of an interim dividend [1]

董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 藥師幫股份有限公司（「本公司」連同其附屬公司及綜合聯屬實體（「本集團」）)董 事（「董 事」）會（「董事會」）兹通告謹定於2025年8月20日（星 期 三）舉 行 董 事 會 會 議， 以（其 中 包 括）考慮及批准本集團截至2025年6月30日止六個月之中期業績及其 發 佈，及 考 慮 派 付 中 期 股 息（如 有）。 承董事會命 藥師幫股份有限公司 主席兼執行董事 張步鎮先生 香 港，2025年8月8日 於 本 公 告 日 期，董 事 會 成 員 包 括 執 行 董 事 張 步 鎮 先 生 及 陳 飛 先 生，非 執 行 董 事 朱 梓 陽 先 生，以 及 獨 立 非 執 行 董 事 邵 蓉 女 士、 ...